Viracta Therapeutics Quote - VIRX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.235

Bid

0.235

Ask

0.25

Volume

490,305

0.231 Day's Range 0.2554

0.1315 52 Week Range 1.31

Market Cap

9.34M

Previous Close

0.25

Open

0.25

Last Trade

1000

0.235

(formt)

Last Trade Time

15:05:42

Financial Volume

US$ 120,100

VWAP

0.244949

Average Volume (3m)

2,324,848

Shares Outstanding

39,744,222

Dividend Yield

PE Ratio

-0.18

Earnings Per Share (EPS)

-1.28

Revenue

Net Profit

-51.06M

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.viracta.com

Headquarters

Wilmington, Delaware, USA

Founded

Viracta Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VIRX. The last closing price for Viracta Therapeutics was US$0.25. Over the last year, Viracta Therapeutics shares have traded in a share price range of US$ 0.1315 to US$ 1.31.

Viracta Therapeutics currently has 39,744,222 shares outstanding. The market capitalization of Viracta Therapeutics is US$9.94 million. Viracta Therapeutics has a price to earnings ratio (PE ratio) of -0.18.

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data...

Form 8-K - Current report

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.022	10.3286384977	0.213	0.257406	0.2003	789198	0.21976356	CS
4	0.085	56.6666666667	0.15	0.257406	0.1399	4231321	0.17838506	CS
12	0.0128	5.76057605761	0.2222	0.2972	0.1315	2324848	0.19255364	CS
26	-0.34	-59.1304347826	0.575	0.6	0.1315	1379509	0.22816485	CS
52	-0.275	-53.9215686275	0.51	1.31	0.1315	748580	0.26587356	CS
156	-3.665	-93.9743589744	3.9	5.75	0.1315	368064	0.96533422	CS
260	-16.525	-98.5978520286	16.76	18.24	0.1315	349186	2.41733637	CS

VIRX - Frequently Asked Questions (FAQ)

What is the current Viracta Therapeutics share price?

The current share price of Viracta Therapeutics is US$ 0.235

How many Viracta Therapeutics shares are in issue?

Viracta Therapeutics has 39,744,222 shares in issue

What is the market cap of Viracta Therapeutics?

The market capitalisation of Viracta Therapeutics is USD 9.94M

What is the 1 year trading range for Viracta Therapeutics share price?

Viracta Therapeutics has traded in the range of US$ 0.1315 to US$ 1.31 during the past year

What is the PE ratio of Viracta Therapeutics?

The price to earnings ratio of Viracta Therapeutics is -0.18

What is the reporting currency for Viracta Therapeutics?

Viracta Therapeutics reports financial results in USD

What is the latest annual profit for Viracta Therapeutics?

The latest annual profit of Viracta Therapeutics is USD -51.06M

What is the registered address of Viracta Therapeutics?

The registered address for Viracta Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Viracta Therapeutics website address?

The website address for Viracta Therapeutics is www.viracta.com

Which industry sector does Viracta Therapeutics operate in?

Viracta Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
EVAXEvaxion Biotech AS	US$ 1.67 (97.28%)	781.27k
SNAXStryve Foods Inc	US$ 0.9628 (45.42%)	502.89k
GVHGlobavend Holdings Ltd	US$ 0.86 (40.89%)	71.25k
MLGOMicroAlgo Inc	US$ 3.25 (14.04%)	770.33k
FEAM5E Advanced Materials Inc	US$ 0.55 (8.23%)	100
BDRXBiodexa Pharmaceuticals PLC	US$ 3.85 (-18.60%)	342
BCGBinah Capital Group Inc	US$ 2.86 (-10.63%)	2.07k
CTCXCarmell Corporation	US$ 0.296 (-7.79%)	4.2k
AIMDAinos Inc	US$ 0.4425 (-7.62%)	1.58k
MMLPMartin Midstream Partners LP	US$ 3.77 (-5.99%)	213.54k
ADTXAditxt Inc	US$ 0.1902 (-0.68%)	1.57M
SOFISoFi Technologies Inc	US$ 16.57 (-0.16%)	1.43M
EYENEyenovia Inc	US$ 0.09 (-0.55%)	849.51k
EVAXEvaxion Biotech AS	US$ 1.67 (97.28%)	781.27k
MLGOMicroAlgo Inc	US$ 3.25 (14.04%)	770.33k